STOCK TITAN

Annexon Inc - ANNX STOCK NEWS

Welcome to our dedicated news page for Annexon (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Annexon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Annexon's position in the market.

Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) outlines global registrational program for ANX007, a first-in-class C1q and classical complement inhibitor, for the treatment of patients with geographic atrophy (GA). The company has gained alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 registration program that includes using the prevention of ≥15-letter loss of best corrected visual acuity (BCVA) as the primary outcome measure. The program will initiate with ARCHER II, a global sham-controlled trial, and ARROW, a head-to-head trial using SYFOVRE® as an injection comparator, expected to initiate in mid-2024 and late 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
-
Rhea-AI Summary
Annexon, Inc. (ANX) reports successful Phase 1 trial results for ANX1502, a first-in-kind oral, selective small molecule inhibitor targeting the active form of C1s. The drug achieved target serum levels, demonstrated supportive impact on a key biomarker, and was generally well tolerated. The company plans to advance a tablet formulation of ANX1502 into a proof-of-concept study in patients with Cold Agglutinin Disease (CAD) in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
-
Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) announces the granting of inducement awards to three new non-executive employees under the 2022 Employment Inducement Award Plan, with options to purchase 108,000 shares of Annexon common stock. The options have a ten-year term, an exercise price per share of $2.79, and vest over 4 years, subject to continued service through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
Rhea-AI Summary
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), will have its president and CEO, Douglas Love, participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The company is developing complement-based medicines for inflammatory-related diseases. A live webcast of the event will be available on the Investors page at www.annexonbio.com, with a replay archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) - Prioritizing ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA), and First-in-Kind Complement Small Molecule, ANX1502. Third quarter 2023 financial results reported. ANX005 Phase 3 Pivotal Data in GBS On Track for First Half of 2024. ANX007 Awarded First-Ever PRIME Designation for the Treatment of GA. ANX1502 Phase 1 Data on Track for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
-
Rhea-AI Summary
ANNX: Annexon, Inc. to Participate in Fireside Chat at 2023 Jefferies London Healthcare Conference. Douglas Love, president and CEO, to discuss complement-based medicines for inflammatory-related diseases. Live webcast available on Annexon website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
conferences
Rhea-AI Summary
Annexon, Inc. has received PRIME designation from the European Medicines Agency (EMA) for its therapeutic candidate ANX007, which showed significant preservation of visual function in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Phase 2 ARCHER trial data demonstrated a durable and dose-dependent impact on visual function, including improved best corrected visual acuity (BCVA). Annexon plans to engage with regulatory authorities to design a global pivotal Phase 3 program for ANX007.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Annexon, Inc. grants inducement to two new non-executive employees under the 2022 Employment Inducement Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary
ANX005 granted orphan drug designation by the European Medicines Agency for the treatment of GBS. Target enrollment achieved in Phase 3 pivotal study. Company on track to report pivotal data in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
Rhea-AI Summary
Annexon, Inc. CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
Annexon Inc

Nasdaq:ANNX

ANNX Rankings

ANNX Stock Data

460.48M
49.27M
8.68%
95.4%
3.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Brisbane

About ANNX

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).